capricor inc capr buy pt capricor demonstr potenti cell therapi
sever covid patient rais price analyst jason mccarthi ph full summari
inc buy pt reduc estim result expect defer work return
vertex pharmaceut incorpor hold covid may holding-up econom growth stop
vertex cf franchis solid quarter maintain hold valuat analyst jason mccarthi ph full summari
aegion corpor hold pt reduc estim base backlog declin weak guidanc
potenti delay order maintain hold pt analyst tate sullivan cfa full summari
inc hold simpl data simpli earli call niaid get remdesivir
immutep limit immp buy pt data continu posit activ space bode
corpor event pleas contact maxim salesperson inform
maxim group infecti diseas virtual confer host mccarthi vendetti tue may
covid may holding-up econom growth
valuat
vertex report beat top bottom line cystic fibrosi
cf product revenu came vs consensu
sequenti non-gaap ep beat consensu vertex
end period cash
rapid uptak trikafta continu drive vertex revenu growth
trikafta revenu came doubl
beat consensu trikafta revenu also seem
somewhat cannib compani product line particular
symdeko came vs consensu kalydeco
orkambi came slightli consensu vs vs
effect vertex comment global suppli chain continu
impact compani remain confid
abil continu suppli cf medicin importantli revenu cf drug
elev quarter earli refil us advanc purchas
ex-u relat
may impact subsequ quarter sequenti growth perspect
view miss forest tree guidanc annual
revenu track growth
conclus domin cystic fibrosi continu like continu
tripl take cf franchis hold rate predic
valuat remain unchang
guidanc increas vertex increas revenu guidanc
non-gaap oper expens effect tax
rate unchang though revenu guidanc increas
repres increas current run rate base suggest
revenu lower rest due combin
factor posit impact neg impact rest
firstli trikafta uptak progress rapidli expect major
elig patient treat pace initi slow addit
on-going pandem cf center limit non-emerg
interact could place pressur growth lastli revenu benefit
increas earli refil well advanc buy ex-u purchas
potenti relat
trikafta updat approv trikafta vertex ad het/min patient
age address market ultim vertex intend expand younger
patient trial expand patient age complet enrol snda
plan increas address market cf
patient patient cover kalydeco orkambi
symdeko patient current elig trikafta compani estim
major treat therapi step ex-u approv
ema current review applic approv submit
australia switzerland well
build beyond cystic fibrosi cash expect cash flow
continu strengthen balanc sheet highlight increas focu
pipelin activ recent includ deal affinia therapeut
privat build gene therapi capabl librari aav capsid
extend research collabor nr develop
discov mrna therapeut cf
pipelin
antitrypsin defici compani two corrector
compani temporarili paus enrol
though process reiniti enrol site-by-sit basi
on-going well
focal segment glomerulosclerosi fsg trial fsg
initi open-label trial design evalu reduct
beta thalassemia b-thal sickl cell diseas scd vertex gene edit
platform remain track provid addit data two trial
year enrol on-going trial howev addit patient
schedul initi dose time
type diabet stem cell-deriv islet sc-islet repres potenti
cur treatment type diabet advanc clinic trial expect
initi late
click full note
reduc estim result expect
defer work return dividend rais
report yesterday post-clos net revenu expect
oper ep expect
although pressur like impact result rest
sept note backlog declin q/q compar
forecast q/q decreas expect defer work due
return
reduc ep modestli
note guidanc withdrawn
announc increas quarterli dividend
forecast repurchas share forecast
maintain buy expect defer work return potenti us
infrastructur stimulu plan catalyst better-than-expect dividend
hike posit signal
higher dividend repurchas support share view even though
limit visibl near-term result result compani
indic long-term confid busi increas quarterli dividend
estim also repurchas
share remain share
guidanc sequenti backlog declin indic lower result near-
term expect reduc guidanc instead withdraw guidanc
link recent updat note last friday also report
backlog declin q/q versu forecast q/q declin
withdrew guidanc net revenu ep base part uncertainti
regard durat stay-at-hom order visibl improv manag
indic may updat outlook end june
reduc estim base lower order commerci custom
decreas ep estim account
risk commerci custom estim net revenu
includ intern commerci client cancel project delay order
current quarter press releas refer project delay cancel
industri sector slightli reduc estim expect
defer work due second half return
review report yesterday post-clos net revenu
forecast consensu analyst oper ep
estim consensu constant currenc
basi net revenu would versu report base
calcul order declin q/q togeth neg
impact result stronger dollar versu foreign currenc also convert
lower amount backlog revenu led lower expect
net revenu ep oper ep y/i exclud
cost primarili relat chang staf level due
maintain buy rate price target share current trade
ep estim base price target revis
ep estim previous base price target round
prior ep estim maintain buy rate base feder
exposur expect water project part us infrastructur
stimulu plan believ foremost water consult world
design water infrastructur improv project us govern would
includ infrastructur plan
compani overview work varieti infrastructur consult project
includ engin solut limit flood damag improv drink water
system among type project
click full note
reduc estim base backlog declin weak
guidanc potenti delay order maintain hold
pt
reduc oper ep estim
report result indic
oper ep compar prior year
report yesterday post-clos revenu ep exceed forecast
consensu driven strong revenu margin energi servic
howev reduc estim backlog decreas q/q
energi servic expect declin lead
guidanc year-ago period better reflect potenti
continu delay order rebound local govern agenc due
maintain hold rate base view state local govern
client continu delay wastewat pipe project
expect driven energi servic report yesterday post-
close revenu y/i consensu
analyst estim oper ep flat y/i
estim consensu upsid due energi servic
revenu revenu increas driven part ad custom also
energi servic oper margin increas prior year
howev backlog
reduc estim guidanc forecast better
reflect potenti order delay manag expect energi servic
revenu declin y/i due reduct refin mainten activ
base part declin decreas oper ep estim
y/i addit better reflect potenti continu
delay order rebound local govern agenc due uncertain budget
reduc oper ep estim y/
y/i may review estim
et earn confer call
secur amend credit facil end
cash announc amend credit facil result base
compani project new leverag coven believ amend
credit facil increas compani borrow capac
end cash debt forecast gener
free cash flow next month reduc debt repurchas share
maintain hold rate price target share current trade
ep forecast reduc base price
target revis ep estim previous base
price target prior ep estim increas price target
multipl base access debt histori gener free cash flow
last three quarter year maintain hold rate base potenti
state local govern client delay wastewat pipe project
compani overview energi infrastructur industri compani
sell product servic extend use life drink sewag water pipe
refineri oil natur ga pipelin
click full note
simpl data simpli earli call niaid
get remdesivir anecdot data hurdl
share two announc relat remdesivir one
initi data non-control simpl studi sever
patient non-ventil depend start trial second
import view announc placebo-control niaid
studi met primari endpoint though data releas yet
data simpl studi continu larg anecdot
control arm valu small key take-away
cours perform similarli expand suppli
placebo-control niaid studi met primari endpoint time
recoveri accord trial design primari endpoint analysi
includ least recov patient niaid expect provid
detail data upcom brief taken total niaid studi
provid hard efficaci data cours treatment
simpl studi data demonstr cours similar
efficaci patient treat earlier effect
bottom line seem progress could call
fauci-factor becom vocal regard recent data
remdesivir one must also consid polit factor surround drug
develop view
initi data simpl studi sever patient gilead two on-going
studi titl simpl studi studi open label
enrol across center first patient sever diseas
studi enrol patient initi data expans across
number countri patient random cours remdesivir
sinc studi control group make judgment efficaci
data difficult said provid insight efficaci
cours vs cours import patient could treat
cours approv emerg author initi data
releas day follow-up clinic improv endpoint primari
endpoint point improv ordin scale point scale measur
death non-hospit patient patient
improv day secondari endpoint patient
day patient demonstr clinic recoveri patient
patient discharg mortal rate patient
patient signific differ efficaci
day cours treatment addit new safeti signal observ though
worth note lead discontinu non-signific trend
observ suggest cours may better toler day
patient vs discontinu addit pool analysi perform
evalu differ earli treatment late treatment earli patient
abl discharg compar patient treat late
niaid studi random double-blind placebo-control remdesivir
thu data studi conclus seen
far gilead announc studi met primari endpoint time recoveri
niaid provid detail upcom brief studi estim
enrol includ patient hospit confirm
well continu page
click full note
capricor demonstr potenti cell
therapi sever covid patient rais price
capricor announc surviv critic ill patient
acut respiratori distress syndrom ard treat iv infus
compani allogen cardio-spher deriv stem cell therapi
capr share
allogen cell therapi demonstr compel data ard
histor power immun modul recent cell
therapi pluristem psti buy plx mesoblast meso buy
capricor demonstr surviv rate
sever covid patient ard mechan
key factor shown
interestingli data rather outcom patient capricor
strikingli similar pluristem plx cell see note
publish link cell therapi covid updat link well earli data
covid mesoblast meso buy signific posit
valid approach sever covid patient
encourag data thu far trial size
still small one consid data anecdot look gilead
lower risk adjust capricor cell therapi platform
rais price target
data compassion use data includ patient
sever ard mechan ventil compani
expand access protocol cedars-sinai medic center cours
month patient receiv infus cell patient ventil
longer requir ventil come averag day infus fifth
patient remain ventil sixth supplement oxygen clinic
stabl addit data add biomark data seen
cell therapi studi covid biomark correl neg outcom
ferritin absolut lymphocyt count crp improv follow
data fda increas expand access protocol add anoth patient
random placebo-control trial also plan moder sever patient
expect fund non-equ capit
cell therapi though data earli emerg potenti import
therapeut capricor make third cell therapi demonstr high rate
surviv among sickest patient ard mechan
ventil ard real killer studi nyc hospit network
report mortal rate high patient ventil importantli
diseas progress point longer viru
hyperact immun respons viru lead cytokin storm
immun system attack lung antivir medic may ideal
set cell therapi demonstr immunomodulatori properti multipl
indic includ ard thu far covid data encourag
mesoblast remestemcel-l matur patient report
surviv rate patient abl come ventil support
median day pluristem also report posit data patient
complet followup demonstr improv respiratori
paramet advanc stage wean ventil demonstr clinic
recoveri multipl organ failur data build grow bodi
data suggest cell therapi could critic part treatment
model updat lower risk adjust across cell therapi platform
base posit data work announc today
effect take price target
click full note
data continu posit activ
space bode immutep
immutep report posit interim data on-going
trial part year american associ
recal collabor merck nr evalu efti
combin keytruda pembrolizumab multicent open-label
studi two cancer type lung head neck
look patient tumor type low medium high pd-
express small patient number efti pembro continu
demonstr overal respons rate orr numer greater
histor pembro alon lung head neck cancer remain
encourag combin data given challeng demonstr
durabl surviv benefit cancer combin key
address void view
data present rememb respons observ
date regardless express
non-smal cell lung cancer nsclc part albeit rel small patient
size orr thu deepen earlier report orr
februari orr report septemb patient
exhibit tumor shrinkag data compar favor histor keytruda
monotherapi respons rate high expressor wherea
respons all-com vari distribut even lower
addit although median progress free surviv yet
reach report month
head neck hnscc part orr seen head neck
consist prior interim look refer keytruda approv base
orr last month patient chemo
patient type orr furthermor patient observ
target tumor shrinkag median yet reach
activ space coincident regeneron nr sanofi sni
nr also announc trial compar libtayo monotherapi
platinum doublet chemotherapi lung cancer stop earli met
primari endpoint overal surviv although would make libtayo
second inhibitor show surviv benefit lung cancer pembro
posit news space studi enrol patient high
express posit tumor cell remain
unmet need treatment patient inhibitor
effect
phase studi collabor merck evalu efti
combin inhibitor keytruda pembrolizumab two cancer type
enrol enrol date across site us eu australia
primari endpoint studi object respons rate orr accord
irecist studi design three cohort part part nsclc
pdx naiv stage fulli enrol stage recruit part nsclc
pdx refractori stage near enrol complet last report stage
begin enrol thereaft part head neck hnscc pdx naiv
 stage fulli enrol stage recruit on-going
financi updat immutep complet equiti financ
share per share repres adss immutep expect
addit fund extend runway end
click full note
maxim analyst coverag univers
sector coverag
care well
industri pharma util ship
receiv full disclosur compani maxim group coverag mention report pleas send
